News

A2 Healthcare Corporation (Headquarters: Bunkyo-ku, Tokyo; President and CEO: Hitoshi Kamiya) has announced the launch of “J-STEP (Japan Strategic Teaming & Entry Program),” a comprehensive support service providing essential functions for overseas pharmaceutical companies entering the Japanese market.

There is growing concern over the widening “drug loss” gap in Japan, where many medicines already approved in the US and Europe remain unavailable to patients domestically. More than half of these unapproved drugs originate from emerging overseas biopharmaceutical companies, underscoring the urgent need for mechanisms that incentivize their active participation in Japan’s drug development landscape.

A2 Healthcare supports overseas pharmaceutical companies in entering the Japanese market. Specifically, we serve as a strategic liaison for overseas pharmaceutical companies and support every stage of new drug introduction domestically, including out-licensing support to Japanese pharmaceutical companies. We collaborate with partner companies such as pharmaceutical wholesalers, CMOs/CDMOs, and non-clinical CROs to provide services from market research, regulatory approval processes, manufacturing, and post-launch distribution, tailored to various modalities and development needs.

Note: IVP stands for ITC Venture Partners, Inc. (Headquarters: California, USA; President & CEO: Suguru Yamaryo). The company provides consulting services that support out-licensing from overseas pharmaceutical companies to Japanese companies.

Going forward, A2 Healthcare will continue to address the social issue of drug loss and fulfil our societal mission of delivering new medical treatments to patients through every step we take brighter future in healthcare.

Here is the release from ITOCHU Corporation.

Contact Details
A2 Healthcare Corporation

Frontier Business Development, Business Development Division
marke@a2healthcare.com